HAPPENING NOW
Long-term leukemia trial reveals MRD-triggered treatment may slow or prevent relapse
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Med…
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an important milestone. The results demonstrate the potential of early, minimal residual disease (MRD)-guided therapy to delay or possibly prevent relapses. RELAZA2…
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNow